Cabot (NYSE:CBT) Stock Price Expected to Rise, Mizuho Analyst Says

Cabot (NYSE:CBT) had its price objective increased by analysts at Mizuho from $103.00 to $122.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the specialty chemicals company’s stock. Mizuho’s price target suggests a potential upside of 4.26% from the company’s previous close.

Several other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Cabot from $95.00 to $105.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. UBS Group dropped their price target on Cabot from $103.00 to $98.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $105.00.

Cabot Price Performance

Shares of NYSE CBT opened at $117.02 on Tuesday. The firm has a market cap of $6.42 billion, a P/E ratio of 17.36, a PEG ratio of 0.91 and a beta of 1.20. Cabot has a twelve month low of $68.11 and a twelve month high of $117.37. The company has a quick ratio of 1.45, a current ratio of 2.22 and a debt-to-equity ratio of 0.72. The company has a 50 day moving average of $108.41 and a 200 day moving average of $101.13.

Cabot (NYSE:CBT) last issued its earnings results on Monday, November 4th. The specialty chemicals company reported $1.80 earnings per share for the quarter, missing analysts’ consensus estimates of $1.81 by ($0.01). The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Cabot had a return on equity of 26.99% and a net margin of 12.05%. Cabot’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period last year, the firm posted $1.65 EPS. As a group, research analysts expect that Cabot will post 7.07 EPS for the current fiscal year.

Insider Buying and Selling at Cabot

In other news, CEO Sean D. Keohane sold 25,617 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total transaction of $2,601,406.35. Following the sale, the chief executive officer now directly owns 331,174 shares of the company’s stock, valued at $33,630,719.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Sean D. Keohane sold 25,617 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $101.55, for a total value of $2,601,406.35. Following the sale, the chief executive officer now owns 331,174 shares in the company, valued at approximately $33,630,719.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Erica Mclaughlin sold 16,390 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $104.24, for a total transaction of $1,708,493.60. Following the transaction, the chief financial officer now owns 59,814 shares of the company’s stock, valued at $6,235,011.36. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,665 shares of company stock worth $4,986,299 in the last quarter. 3.07% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cabot

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Natixis Advisors LLC boosted its holdings in shares of Cabot by 14.6% in the 3rd quarter. Natixis Advisors LLC now owns 116,011 shares of the specialty chemicals company’s stock worth $12,967,000 after purchasing an additional 14,740 shares during the period. Oppenheimer Asset Management Inc. boosted its stake in Cabot by 2.9% during the third quarter. Oppenheimer Asset Management Inc. now owns 43,484 shares of the specialty chemicals company’s stock worth $4,860,000 after buying an additional 1,244 shares during the period. Aigen Investment Management LP purchased a new stake in shares of Cabot in the third quarter valued at $482,000. Entropy Technologies LP bought a new stake in shares of Cabot in the 3rd quarter worth about $701,000. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Cabot by 25.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 23,794 shares of the specialty chemicals company’s stock worth $2,659,000 after purchasing an additional 4,756 shares during the period. 93.18% of the stock is currently owned by hedge funds and other institutional investors.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.